ReportsnReports.com: R&D Trends: Obesity - 2006–2011: Obesity’s Lean Years
Modest efficacy results and lingering safety concerns have meant that developers of obesity drugs have failed to convince regulators of their risk-benefit profiles. The continued escalation of safety requirements in the light of recent withdrawals might see another raft of discontinuations, as Datamonitor views the chances of the late-stage pipeline candidates expanding the obesity market as slim
View full press release